2026-05-17T05:52:43Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/199372024-11-29T00:38:55Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Bernal, Teresa
author
Pardavila, Estefania V.
author
Bonastre, Juan
author
Jarque, Isidro
author
Borges Sa, Marcio
author
Bargay Lleonart, Joan
author
Ignacio Ayestaran, Jose
author
Insausti, Josu
author
Marcos, Pilar
author
Gonzalez-Sanz, Victor
author
Martinez-Camblor, Pablo
author
Albaiceta, Guillermo M.
2024-07-03T11:01:10Z
2024-07-03T11:01:10Z
2013
Bernal T, Pardavila EV, Bonastre J, Jarque I, Borges Sa M, Bargay Lleonart J, et al. Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. Crit Care. 2013;17(6):R302.
10.1186/cc13172
1364-8535
1466-609X
Critical Care
http://hdl.handle.net/20.500.13003/11410
24377481
L52941881
2-s2.0-84891349597
http://hdl.handle.net/20.500.12105/19937
332293100001
Introduction: Although the survival rates of hematological patients admitted to the ICU are improving, little is known about the long-term outcome. Our objective was to identify factors related to long-term outcome in hematological patients after ICU discharge. Methods: A prospective, observational study was carried out in seven centers in Spain. From an initial sample of 161 hematological patients admitted to one of the participating ICUs during the study period, 62 were discharged alive and followed for a median time of 23 (1 to 54) months. Univariate and multivariate analysis were performed to identify the factors related to long term-survival. Finally, variables that influence the continuation of the scheduled therapy for the hematological disease were studied. Results: Mortality after ICU discharge was 61%, with a median survival of 18 (1 to 54) months. In the multivariate analysis, an Eastern Cooperative Oncology Group score (ECOG) >2 at ICU discharge (Hazard ratio 11.15 (4.626 to 26.872)), relapse of the hematological disease (Hazard ratio 9.738 (3.804 to 24.93)) and discontinuation of the planned treatment for the hematological disease (Hazard ratio 4.349 (1.286 to 14.705)) were independently related to mortality. Absence of stem cell transplantation, high ECOG and high Acute Physiology and Chronic Health Evaluation II (APACHE II) scores decreased the probability of receiving the planned therapy for the hematological malignancy. Conclusions: Both ICU care and post-ICU management determine the long-term outcome of hematological patients who are discharged alive from the ICU.
eng
Survival of hematological patients after discharge from the intensive care unit: a prospective observational study
research article